Canada Markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
87.03-1.16 (-1.32%)
At close: 04:00PM EST
87.24 +0.21 (+0.24%)
After hours: 07:41PM EST

Novartis AG

Lichtstrasse 35
Basel 4056
41 61 324 1111

IndustryDrug Manufacturers—General
Full Time Employees108,000

Key Executives

NameTitlePayExercisedYear Born
Dr. Vasant NarasimhanChief Exec. Officer5.08MN/A1976
Mr. Harry KirschChief Financial Officer2.68MN/A1965
Mr. Steffen Lang Ph.D.Global Head of Technical Operations2.02MN/A1967
Dr. Klaus Moosmayer Ph.D.Chief Ethics, Risk & Compliance Officer1.33MN/A1968
Dr. John TsaiHead of Global Drug Devel. & Chief Medical Officer2.3MN/A1967
Mr. Robert WeltevredenHead of Customer & Technology Solutions1.57MN/A1969
Ms. Susanne Schaffert Ph.D.Pres of Novartis Oncology3.01MN/A1967
Mr. Richard SaynorChief Exec. Officer of Sandoz3.8MN/A1967
Dr. James E. Bradner M.D.Pres of Novartis Institutes for Biomedical Research3.2MN/A1972
Ms. Marie-France TschudinPres of Novartis Pharmaceuticals2.1MN/A1971
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AG’s ISS Governance QualityScore as of September 26, 2021 is 2. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.